-- Experienced start-up technology leader in biomolecule drug discovery with strong emphasis on DNA library design, selections, and High Throughput Screening as well as manufacturing scale-up, in the areas of oncology, coagulation, and inflammation.--Protein engineering expertise in biologics lead identification/optimization using phage, E. coli, yeast, & ribosome display, structure-based design of site-specific antibody-drug ligand conjugates (ADCs), non-IgG scaffolds, fusion proteins, bispecific antibodies (bsAbs), and early preclinical development of ADCs, therapeutic proteases, and a novel targeted enzyme pro-drug therapy.--Experience in managing strategic technical relationships and alliances with internal teams, external partners, and VCs including technology validation of engineered non-natural amino acid (nnAA) containing proteins leading to $37M Series C funding and multiple research collaborations.--Co-inventor on 25 patent/patent applications and co-author on 41 publications in major peer-reviewed journals, 36 as first or senior author.